Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?;Može li Odredivanje Lp-PLA2 Pomoći u Predvidanju Ateroskleroze i Kardiocerebrovaskularnih Bolesti?

Acta Medica Croatica

Volumn 64, Issue 4, 2010, Pages 237-245

  Sertic J ^a   Skoric B ^a   Lovric J ^b   Bozina T ^a   Reiner, Z ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Department of Medical Chemistry Biochemistry and Clinical Chemistry ^*  (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Atherosclerosis; Biomarkers; Coronary heart disease; Lp PLA2; Risk factor; Rupture prone plaque

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 79960093428     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol 2008;101(Suppl.12A): 3F-10F.
2. Anderson JL. Lipoprotein-associated phospholipase A2: and independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008; 101(Suppl.12A): 23F-33F.
3. Kolodgie FD, Burek AP, Skorija KS i sur. Lipoprotein- associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523-9. (Pubitemid 44607475)
4. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: C13-C18.
5. Kuvin JT, Dave DM, Sliney KA i sur. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006; 98: 743-5. (Pubitemid 44301006)
6. Shalwitz RA, Maki KC, Doyle RT, Ballantyne CM. Lipoprotein subfraction responses differentially predict changes in lipoprotein-associated phospholipase A2 (Lp- PLA2) during prescription omega-3 therapy. Program and abstracts of the Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2007; April 19-21, 2007; Chicago, Illinois. Abstract P383.
7. Leon AS, Wilmore JH, Ewy GA i sur. Endurance exercise training reduces lipoprotein-associated phospholipase A2 (Lp-PLA2) in young white adults: the HERITAGE family study. Med Sci Sports Exerc 2007; 39(suppl): S312.
8. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-8. (Pubitemid 38063699)
9. McLaughlin TM, Abbasi F, Wolfert R, Lamendola C, Reaven G, Reaven P. Lipoprotein-associated phospholipase A2 is not increased in association with insulin resistance [abstract]. Arterioscler Thromb Vasc Biol 2004; 24: E-67.
10. Ballantyne CM, Hoogeveen RC, Bang H i sur. Lipoprotein- associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42. (Pubitemid 38252734)
11. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospolipase A2 adds to risk prediction of incident coronary events by Creactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow- up of a large cohort from souther Germany (MONICA- Augsburg). Circulation 2004; 110: 1903-08. (Pubitemid 39331899)
12. May HT, Horne BD, Anderson JL i sur. Lipoprotein- associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006; 152: 997-1003. (Pubitemid 44632932)
13. Nambi V, Hoogeveen RC, Chambliss L i sur. Lipoprotein- associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2009;40:376-81.
14. Tsimikas S, Willeit J, Knoflach M i sur. Lipoprotein- associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Europ Heart J 2008;30:107-115.
15. Gerber Y, Dunlay SD, Jaffe AS i sur. Plasma lipoprotein- associated phospholipase A2 levels in heart failure: Association with mortality in the community. Atherosclerosis 2009;203:593-8.
16. Brilakis ES, Khera A, Saeed B, Banerjee S, McGuire DK, Murphy SA, de Lemos JA. Association of lipoprotein- associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: Findings from the Dallas Heart Study. Clin Chem 2008; 54: 1975-81. (Pubitemid 352774030)
17. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke. A population-based cohort study from Malmo, Sweden. Atherosclerosis 2008; 200: 191-8.
18. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1411-16. (Pubitemid 46823453)
19. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006; 52: 1331-8. (Pubitemid 43956025)
20. Folsom AR, Chambless LE, Ballantyne CM i sur. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med 2006; 166: 1368-73. (Pubitemid 44036348)
21. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the Community. Arterioscler Thromb Vasc Biol 2006; 26: 2517-22. (Pubitemid 44607474)
22. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Arterioscler Thromb Vasc Biol 2006; 26: 1586-93. (Pubitemid 44288987)
23. May HT, Horne BD, Anderson JL i sur. Lipoprotein- associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006; 152: 997-1003. (Pubitemid 44632932)
24. O'Donoghue M, Morrow DA, Sabatine MS i sur. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin evaluation and infection therapy - thrombolysis in myocardial infarction) trial. Circulation 2006; 113: 1745-52. (Pubitemid 43958467)
25. Lavi S, McConnell JP, Rihal CS i sur. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007; 115: 2715-21. (Pubitemid 46842787)
26. Zalewski A, Nelson JJ, Hegg L, MacPhee C. Lp- PLA2: a new kid on the block. Clin Chem 2006; 52: 1645- 50.
27. Mannheim D, Herrmann J, Versari D i sur. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008; 39: 1448-55.
28. Wassertheil-Smoller S, Kooperberg C, McGinn AP i sur. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008; 51: 1115-22. (Pubitemid 351398957)
29. Gorelick PB. Lipoprotein-associated phospholipase A2: and risk of stroke. Am J Cardiol 2008; 101 (Suppl.12A): 34F-40F.
30. Wilinsky RL, Mohler ER, Hamamdzic D i sur. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nature Med 2008; 14: 1059-66.
31. Rosenson RS. Fenofibrate reduces lipoproteinassociated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J 2008; 155: 499.e9-16.
32. Anderson JL. Lp-PLA2: an independent predictor of CHD events in primary and secondary prevention. Am J Cardiol 2008;101[suppl]: 23F-33F.
33. Smith SC, Allen J, Blair SN i sur. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: 2362-72.
34. Davidson MH, Corson MA, Alberts MJ i sur. Consensus panel recommendation for incorporating lipoprotein- associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101(Suppl.12A): 51F-57F.
35. Graham I, Atar D, Borch-Johnsen K i sur.European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-2414.